An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor

Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study

(2022) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy : The multicenter prospective cohort GARLIT study

(2022) Fabrizio Vernieri et al.   EUROPEAN JOURNAL OF NEUROLOGY

Migraine therapeutics differentially modulate the CGRP pathway

(2021) Minoti Bhakta et al.   CEPHALALGIA

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

(2021) Fabrizio Vernieri et al.   JOURNAL OF HEADACHE AND PAIN

Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis

(2021) Xing Wang et al.   Frontiers in Pharmacology

Timing and durability of response to erenumab in patients with chronic migraine

(2021) Stewart J. Tepper et al.   HEADACHE

Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine

(2021) Min Shi et al.   NEUROLOGICAL RESEARCH

Predictors of response to erenumab after 12 months of treatment

(2021) Carlo Baraldi et al.   Brain and Behavior

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study

(2021) Lucas Hendrik Overeem et al.   CEPHALALGIA

Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis

(2021) Prashant Soni et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study

(2021) Fabrizio Vernieri et al.   EUROPEAN JOURNAL OF NEUROLOGY

Clinic and genetic predictors in response to erenumab

(2021) Chiara Zecca et al.   EUROPEAN JOURNAL OF NEUROLOGY

Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine

(2020) Jennifer Robblee et al.   HEADACHE

LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY

(2020) Peter J. Goadsby et al.   NEUROLOGY

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

(2019) Peter J Goadsby et al.   CEPHALALGIA

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

CGRP, Amylin, Immunology, and Headache Medicine

(2018) Frederick R. Taylor   HEADACHE

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Blocking CGRP in migraine patients – a review of pros and cons

(2017) Marie Deen et al.   JOURNAL OF HEADACHE AND PAIN

Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission

(2017) Rebecca E. Yarwood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles

(2016) Debbie L. Hay et al.   Annual Review of Pharmacology and Toxicology